Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vyteris Inc.

www.vyteris.com

Latest From Vyteris Inc.

Drug Delivery Partnership Strategies – Case studies in effective licensing, collaboration and therapeutic differentiation

Innovative drug delivery technologies are playing an increasingly important role in extending lifecycles, differentiating me-too products and unlocking the value of new compounds with challenging delivery requirements, writes Steven Seget in a report from Scrip Insights.

Companies Deals

Recent Tech Transfer Deals (10/2010)

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

What's Topical? Devices for Transdermal Drug Delivery

The drug delivery device industry is on track to reach almost $23 billion by the year 2011, and the fastest growth will come from the transdermal sector. According to a recent Windhover Information/Medtech Insight report, transdermal delivery technologies will build up to sales of $4.6 billion by 2011. Pharma's increasing fondness for macromolecules will fuel that growth, as will the perennially hot market for transdermal formulations of pain drugs.
BioPharmaceutical Medical Device

Drug Delivery Companies Hop On the Transdermal Express

Transdermal drug delivery has come a long way since the first patch for seasickness. In a drug delivery device industry on track to reach almost $23 billion by the year 2011 (according to "US Markets for Drug and Fluid Delivery Devices," published in October 2007 by Windhover Information's Medtech Insight division) the transdermal sector will grow at a faster rate than injection or inhalation drug delivery systems. Transdermal delivery technologies will grow at a compound annual rate of more than 11% over the next four years, building up to sales of $3.5 billion in the year 2011.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Transdermal
  • Therapeutic Areas
  • Gynecological, Urological
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Vyteris Holdings Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vyteris Inc.
  • Senior Management
  • Haro Hartounian, PhD, Pres. & CEO
    Joseph Himy, CFO
    Michael Reidy, PhD, VP, R&D
    Eric Pluckhorn, SVP, Sales & Mktg.
  • Contact Info
  • Vyteris Inc.
    Phone: (201) 703-2299
    13-01 Pollitt Dr.
    Fair Lawn, NJ 07410
    USA
UsernamePublicRestriction

Register